JP Morgan Chase’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-27,900
| Closed | -$1.07M | – | 7402 |
|
|
2024
Q2 | $1.07M | Hold |
27,900
| – | – | ﹤0.01% | 4226 |
|
|
2024
Q1 | $1.64M | Buy |
27,900
+25,100
| +896% | +$1.6M | ﹤0.01% | 3999 |
|
|
2023
Q4 | $168K | Sell |
2,800
-74,300
| -96% | -$3.77M | ﹤0.01% | 5488 |
|
|
2023
Q3 | $2.93M | Buy |
+77,100
| New | +$3.39M | ﹤0.01% | 3255 |
|
|
2023
Q2 | – | Sell |
-183,800
| Closed | -$12.1M | – | 6898 |
|
|
2023
Q1 | $12.1M | Buy |
+183,800
| New | +$10.6M | ﹤0.01% | 2105 |
|
|
2022
Q4 | – | Sell |
-45,000
| Closed | -$3.07M | – | 6517 |
|
|
2022
Q3 | $3.07M | Buy |
+45,000
| New | +$2.66M | ﹤0.01% | 3135 |
|
|
2022
Q2 | – | Sell |
-43,300
| Closed | -$2.2M | – | 6438 |
|
|
2022
Q1 | $2.2M | Buy |
+43,300
| New | +$1.91M | ﹤0.01% | 3673 |
|
|
2021
Q4 | – | Sell |
-51,700
| Closed | -$1.7M | – | 6613 |
|
|
2021
Q3 | $1.7M | Buy |
+51,700
| New | +$2.9M | ﹤0.01% | 3914 |
|
|
2020
Q1 | – | Sell |
-68,600
| Closed | -$2.1M | – | 5273 |
|
|
2019
Q4 | $2.1M | Buy |
+68,600
| New | +$1.9M | ﹤0.01% | 3347 |
|
Other funds holding APLS
JP Morgan Chase's APLS Position: Q2 2026 in Review
JP Morgan Chase sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 2,047,927 shares — an estimated $35M sold.
JP Morgan Chase first reported a position in APLS in Q4 2017 and held it in 34 quarters. The position peaked at $163M in Q2 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- JP Morgan Chase reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- JP Morgan Chase sold 2,047,927 Apellis Pharmaceuticals shares in Q2 2026, an estimated $35M.
- JP Morgan Chase first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 34 quarters.
- JP Morgan Chase's Apellis Pharmaceuticals position peaked at $163M in Q2 2023.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.